Clinical Trial: The IVO-LUNG Study

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204548) titled 'The IVO-LUNG Study' on Sept. 02.

Brief Summary: This Phase II, open-label, single-arm study evaluates the efficacy and safety of one-year Ivonescimab consolidation therapy in patients with unresectable Stage III NSCLC who have not progressed after definitive chemoradiotherapy.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer (Stage III)

Intervention: DRUG: Ivonescimab

Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sun Yat-sen University

Information provided by (Responsible Party): Li-kun Chen, Sun Yat-...